دورية أكاديمية
أعرض في EDS

Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression.

التفاصيل البيبلوغرافية
العنوان: Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression.
المؤلفون: Song S; Department of Biology, Baylor University, Waco, TX 76706, USA., Johnson KS; Department of Biology, Baylor University, Waco, TX 76706, USA., Lujan H; Department of Environmental Science, Baylor University, Waco, TX 76706, USA., Pradhan SH; Department of Environmental Science, Baylor University, Waco, TX 76706, USA., Sayes CM; Department of Environmental Science, Baylor University, Waco, TX 76706, USA., Taube JH; Department of Biology, Baylor University, Waco, TX 76706, USA.
المصدر: Non-coding RNA [Noncoding RNA] 2021 Jul 27; Vol. 7 (3). Date of Electronic Publication: 2021 Jul 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101652294 Publication Model: Electronic Cited Medium: Internet ISSN: 2311-553X (Electronic) Linking ISSN: 2311553X NLM ISO Abbreviation: Noncoding RNA Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2015]-
مستخلص: Triple-negative breast cancers affect thousands of women in the United States and disproportionately drive mortality from breast cancer. MicroRNAs are small, non-coding RNAs that negatively regulate gene expression post-transcriptionally by inhibiting target mRNA translation or by promoting mRNA degradation. We have identified that miRNA-203, silenced by epithelial-mesenchymal transition (EMT), is a tumor suppressor and can promote differentiation of breast cancer stem cells. In this study, we tested the ability of liposomal delivery of miR-203 to reverse aspects of breast cancer pathogenesis using breast cancer and EMT cell lines. We show that translationally relevant methods for increasing miR-203 abundance within a target tissue affects cellular properties associated with cancer progression. While stable miR-203 expression suppresses LASP1 and survivin, nanoliposomal delivery suppresses BMI1, indicating that suppression of distinct mRNA target profiles can lead to loss of cancer cell migration.
References: J Cell Mol Med. 2011 Dec;15(12):2760-7. (PMID: 21323860)
J Oncol. 2015;2015:865816. (PMID: 25883654)
PLoS One. 2014 Aug 20;9(8):e105570. (PMID: 25140799)
Adv Drug Deliv Rev. 2015 Jan;81:142-60. (PMID: 25450259)
PLoS One. 2015 Sep 18;10(9):e0132225. (PMID: 26382657)
EMBO Rep. 2008 Jun;9(6):582-9. (PMID: 18483486)
Gynecol Oncol. 2014 May;133(2):340-5. (PMID: 24530564)
Cell. 2009 Jan 23;136(2):215-33. (PMID: 19167326)
Oncogene. 2019 Apr;38(16):3061-3076. (PMID: 30617305)
Oncogene. 2016 Nov 17;35(46):5977-5988. (PMID: 27292262)
Annu Rev Pathol. 2014;9:287-314. (PMID: 24079833)
Nature. 2006 May 25;441(7092):537-41. (PMID: 16724069)
Clin Cancer Res. 2011 Aug 15;17(16):5287-98. (PMID: 21159887)
Nat Rev Drug Discov. 2010 Oct;9(10):775-89. (PMID: 20885409)
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11494-11499. (PMID: 29073077)
Cancer Res. 2013 Apr 15;73(8):2412-7. (PMID: 23423979)
Int J Nanomedicine. 2012;7:49-60. (PMID: 22275822)
Mol Cell. 2001 Jun;7(6):1267-78. (PMID: 11430829)
Silence. 2012 Jan 09;3(1):1. (PMID: 22230293)
NPJ Breast Cancer. 2016 Nov 16;2:16036. (PMID: 28721389)
Mol Cell Biol. 2008 Aug;28(15):4772-81. (PMID: 18519590)
Cancer J. 2012 May-Jun;18(3):275-84. (PMID: 22647365)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Dev Cell. 2019 May 6;49(3):361-374. (PMID: 31063755)
PLoS One. 2015 Jul 01;10(7):e0131350. (PMID: 26132195)
Int J Nanomedicine. 2020 Mar 19;15:1903-1914. (PMID: 32256067)
Nat Rev Cancer. 2017 Jan;17(1):20-37. (PMID: 27834398)
Mol Carcinog. 2017 Feb;56(2):464-477. (PMID: 27253631)
Trends Pharmacol Sci. 2009 Nov;30(11):592-9. (PMID: 19837467)
Cancer Res. 2014 Nov 1;74(21):6330-40. (PMID: 25164016)
Genes Cancer. 2011 Jul;2(7):720-7. (PMID: 22207897)
Onco Targets Ther. 2016 Oct 11;9:6203-6210. (PMID: 27785068)
Nat Biotechnol. 2020 Jun;38(6):675-678. (PMID: 32444850)
Nat Cell Biol. 2010 Oct;12(10):982-92. (PMID: 20818389)
Cancer Res. 2008 Oct 1;68(19):7846-54. (PMID: 18829540)
BMC Cancer. 2014 Oct 28;14:785. (PMID: 25348805)
Sci Rep. 2013;3:2687. (PMID: 24045437)
Nat Commun. 2018 Nov 7;9(1):4671. (PMID: 30405106)
J Biol Chem. 2014 Jan 3;289(1):529-39. (PMID: 24247238)
Nat Cell Biol. 2017 May;19(5):518-529. (PMID: 28414315)
Annu Rev Pathol. 2009;4:199-227. (PMID: 18817506)
Nat Cell Biol. 2009 Dec;11(12):1487-95. (PMID: 19935649)
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (PMID: 24556840)
Oncol Res. 2018 Sep 14;26(8):1155-1165. (PMID: 28893347)
Cell Cycle. 2012 Apr 1;11(7):1291-5. (PMID: 22421148)
Cancer Lett. 2011 May 1;304(1):52-9. (PMID: 21354697)
PLoS One. 2018 Feb 2;13(2):e0190245. (PMID: 29394261)
Genes Cancer. 2011 Aug;2(8):782-91. (PMID: 22393463)
Mol Oncol. 2014 Feb;8(1):83-92. (PMID: 24145123)
Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
Cell Rep. 2014 Oct 9;9(1):104-117. (PMID: 25284788)
Int J Nanomedicine. 2019 Jul 11;14:5159-5173. (PMID: 31371954)
Nanomedicine. 2013 Jan;9(1):1-14. (PMID: 22684017)
Nat Rev Genet. 2008 Feb;9(2):102-14. (PMID: 18197166)
Oncotarget. 2015 Apr 20;6(11):8914-28. (PMID: 25871397)
IUBMB Life. 2018 Mar;70(3):224-236. (PMID: 29389061)
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):. (PMID: 28096261)
J Exp Clin Cancer Res. 2012 Jun 19;31:58. (PMID: 22713668)
Oncol Lett. 2015 Jun;9(6):2639-2646. (PMID: 26137120)
Cancer Cell. 2008 Jun;13(6):496-506. (PMID: 18538733)
Cell Rep. 2019 Nov 5;29(6):1458-1468.e3. (PMID: 31693888)
Nature. 2007 Jun 28;447(7148):1130-4. (PMID: 17554337)
EMBO Rep. 2010 Sep;11(9):670-7. (PMID: 20706219)
Cancer Discov. 2013 Nov;3(11):1302-15. (PMID: 24002999)
Oncotarget. 2014 Jun 30;5(12):4144-4153. (PMID: 24980827)
EMBO Mol Med. 2015 Apr 14;7(6):831-47. (PMID: 25872941)
Mol Cancer Ther. 2011 Aug;10(8):1470-80. (PMID: 21622730)
Genes Dev. 2003 May 15;17(10):1253-70. (PMID: 12756227)
Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099)
Nat Cell Biol. 2019 Jan;21(1):102-112. (PMID: 30602760)
Int Immunol. 2012 May;24(5):293-301. (PMID: 22336533)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
J Biosci Bioeng. 2015 Oct;120(4):351-8. (PMID: 25910964)
Cancer Res. 2010 Jul 15;70(14):5923-30. (PMID: 20570894)
فهرسة مساهمة: Keywords: EMT; breast cancer; microRNA; microRNA-203; nanoliposome; nanoparticle
تواريخ الأحداث: Date Created: 20210827 Latest Revision: 20230920
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8395754
DOI: 10.3390/ncrna7030045
PMID: 34449670
قاعدة البيانات: MEDLINE
الوصف
تدمد:2311-553X
DOI:10.3390/ncrna7030045